PRODUCT LAUNCH IN INDIA
DiaGenic and Super Religare Laboratories (SRL) have launched the breast cancer test BCtect™ in the Indian market. The launch took place on the 8th November at the Royal Norwegian Embassy in Delhi.
During her address, the Norwegian ambassador, Mrs Ann Ollestad, said “Representing Norway in India on a day where we together can present a new and revolutionary test for early breast cancer detection is a great privilege. Representing all women – both in India, Norway and all other countries – on a day that gives hope for women to fight breast cancer is a great moment for the future”.
SRL expressed their satisfaction with the choice of India for the first launch, globally, of BCtect™, the first product from DiaGenic. SRL have now launched the test in the Dehli-area, where it is now available at over 100 collection centres. SRL stated that during the coming months further rollout will take place at the major cities in India, and announced that the maximum retail price for the test will be 14,750 INR (approximately 2,200 NOK).
Dr. Med. Erik Christensen, Chief Executive Officer of DiaGenic commented “We are pleased that the first product launch has taken place, and that a commercial product from DiaGenic is now available on the market. It is a clear ambition of the company to achieve earnings and to harvest the benefits of 10 years research and development. SRL are making substantial efforts to ensure that the test reaches the intended market. DiaGenic will actively support their marketing activities, whilst at the same time preparing the launch of both the BCtect™ and Alzheimer’s test, ADtect™, in Europe.
The company has previously communicated that they will receive a net margin of approximately 300 NOK per sold test. The company will report sales volumes achieved on a quarterly basis.
DiaGenic’s Indian co-founder, Praveen Sharma, commented “It was personally a great pleasure for me to participate in the launch of our first commercial product here in India. I am very pleased that we chose to perform a large clinical study here in India, and that the results from the study have laid the foundations for the product launch.
International press releases from SRL and DiaGenic, and Applied Biosystems and DiaGenic, are enclosed.
Contact:
MD PhD Erik Christensen, Managing Director
Telephone: +47 95939918
e-mail: erik.christensen@diagenic.com